{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:52:50Z","timestamp":1782172370370,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011349","name":"University of Texas at El Paso","doi-asserted-by":"publisher","award":["(AID-OAA-A-13-00084"],"award-info":[{"award-number":["(AID-OAA-A-13-00084"]}],"id":[{"id":"10.13039\/100011349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vaccine.2019.01.067","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T09:31:49Z","timestamp":1550136709000},"page":"1642-1650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12\u0394NSm21\/384 vaccine candidate for sheep, goats and calves"],"prefix":"10.1016","volume":"37","author":[{"given":"Z.","family":"Boumart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Daouam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Bamouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jazouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.O","family":"Tadlaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Elharrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.01.067_b0005","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"IRC. ICTV virus taxonomy profile: pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0010","unstructured":"ICTV Virus Taxonomy. Genus: Pegivirus \u2013 Flaviviridae \u2013 Positive-sense RNA Viruses \u2013 International Committee on Taxonomy of Viruses (ICTV). 10th Rep Int Comm Taxon Viruses; 2017. <https:\/\/talk.ictvonline.org\/ictv-reports\/ictv_online_report\/positive-sense-rna-viruses\/w\/flaviviridae\/363\/genus-pegivirus>."},{"key":"10.1016\/j.vaccine.2019.01.067_b0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3201\/eid1902.120941","article-title":"Rift Valley Fever and a new paradigm of research and development for zoonotic disease control","volume":"19","author":"Dar","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0020","doi-asserted-by":"crossref","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from east africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Zoonosis Update Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2019.01.067_b0035","article-title":"Recent outbreaks of rift valley fever in east africa and the middle East","volume":"2","author":"Himeidan","year":"2014","journal-title":"Front Public Heal"},{"key":"10.1016\/j.vaccine.2019.01.067_b0040","first-page":"825","article-title":"Infectious diseases of livestock with special reference to Southern Africa","author":"Thomson","year":"1994","journal-title":"Foot-and-mouth Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/ojvr.v80i1.384","article-title":"Temporal and spatial history of Rift Valley fever in South Africa: 1950 to 2011","volume":"80","author":"Pienaar","year":"2013","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0050","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","article-title":"Rift Valley fever epizootic in Egypt 1977\u201378. 1. Description of the epizzotic and virological studies","volume":"73","author":"The","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.01.067_b0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(16)30477-7","article-title":"Rift valley fever epidemic in Niger near border with Mali","volume":"16","author":"Tambo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","article-title":"Rift Valley fever: an uninvited zoonosis in the Arabian peninsula","volume":"21","author":"Balkhy","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2019.01.067_b0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004550","article-title":"Fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0075","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0080","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","article-title":"Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves","volume":"29","author":"Von Teichman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0085","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0090","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0105","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift valley fever virus vaccine in fetal and neonatal bovids","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jir354","article-title":"Mucosal immunization of rhesus macaques with rift valley fever MP-12 vaccine","volume":"204","author":"Morrill","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0125","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2019.01.067_b0130","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of rift valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.01.067_b0140","doi-asserted-by":"crossref","DOI":"10.3791\/3400","article-title":"Using reverse genetics to manipulate the NSs gene of the Rift Valley Fever virus MP-12 strain to improve vaccine safety and efficacy","author":"Kalveram","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2019.01.067_b0145","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0150","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0155","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","volume":"32","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.067_b0160","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2019.01.067_b0165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/vbz.2009.0205","article-title":"Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates","volume":"10","author":"Busquets","year":"2010","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2019.01.067_b0170","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.5897\/AJPP11.393","article-title":"A modified arithmetical method of Reed and Muench for determination of a relatively ideal median lethal dose (LD50)","volume":"5","author":"Saganuwan","year":"2011","journal-title":"African J Pharm"},{"key":"10.1016\/j.vaccine.2019.01.067_b0175","unstructured":"Authenticated U.S government information; animal and plant health inspection service, USDA n.d.; 113\u201355:701\u20132."},{"key":"10.1016\/j.vaccine.2019.01.067_b0180","unstructured":"European Pharmacopeia OIE 2008; 1.1."},{"key":"10.1016\/j.vaccine.2019.01.067_b0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4269\/ajtmh.2010.09-0288","article-title":"An investigation of a major outbreak of rift valley fever in Kenya: 2006\u20132007","volume":"83","author":"Nguku","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.01.067_b0190","unstructured":"OIE terrestrial manual, Peste des Petits Ruminants 2013; 2.7.11:1\u201314."},{"key":"10.1016\/j.vaccine.2019.01.067_b0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of Clone 13, a naturally attenuated avirulent isolate of Rift Valley Fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.01.067_b0200","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0205","article-title":"Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells","author":"Lokugamage","year":"20172","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.01.067_b0210","doi-asserted-by":"crossref","DOI":"10.1099\/0022-1317-77-12-3053","article-title":"Persistent infection of mammalian cells by Rift Valley fever virus","volume":"77","author":"Billecocq","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.01.067_b0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.01.067_b0220","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta Pathol Microbiol Immunol Scand C"},{"key":"10.1016\/j.vaccine.2019.01.067_b0225","first-page":"295","article-title":"Evaluation of the safety and efficacy of a live attenuated thermostable Rift Valley fever vaccine in sheep, Goats and Cattle","volume":"6","author":"Daouam","year":"2015","journal-title":"Vaccines Vaccin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19301525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19301525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:47Z","timestamp":1759401047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19301525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0264410X19301525"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12\u0394NSm21\/384 vaccine candidate for sheep, goats and calves","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}